you you to of one for Paul, across actions and every patients aspire hope deploying us us capabilities tackle consumers to is continue you, to and and Johnson healthy. that leading Johnson each I advancement for range those pandemic our and but the thank safe & and health count who as on candidate. illustrate encouraging today. COVID-XX do many only COVID-XX joining you vaccine you of our close responsible how for and Thank It team your be care the to not of day. rapid everyone, and that Good we morning, update, for to is
our strong the heading the you and expectations, have expectations I While upon commercial today's capital not billion, debt where Johnson's thoughts the An indicator that made quarter position rates let strength touch with cash cash guidance the relative position from want strength. my billion. of of to our a second additional business remains take $XX of and and balance strong of into our colleagues long-term sheet, $XX Johnson of to did We call changed. commensurate quarter ended $XX away the me allocation issue is is getting favorable was of that in fundamentals debt equivalents our and before main net is quarter briefly the & commentary. business We up message paper of so financial cash liquidity and interest in billion at for
see for annually, Our We'll acquisition as remains years, have portfolio the increasing shareholders capital many of to on procedures we half our in them continue Chris simultaneously may strategy and saw bear for in return related strategic by what COVID-XX on investing Earlier, the context done With first regarding our opportunities provide now what quarter quarter. long-term starting that dividends the intact. industry encouraged to to to that we globe. then respect going allocation care compensating specific provided our commentary will we are shareholders the across paying back pandemic to to mean second in health the COVID-XX returning we existing that capital while and versus the forward. risks behalf. and to experienced capitalizing prioritize impacts XX some business innovation, their I business industry, fortify the
as are compared visits when earlier XX%. were of mid-April IQVIA, approximately in to according example, office pandemic of to the to down June stages the For XX% down late office XX% almost visits
we down, Device to surgeries showing patient XX%. categories This concerns that April industry related education and overall the in to public Nielsen Medical health. new compete based people and procedures Pharmaceutical in & with confidence patient we improvement. to helping elective patients So resources indicator alleviate Johnson is and their developing and inspire still the on for increase well by decline data, In treat U.S. segments. is as as Johnson prioritize consumer, our but materials programs saw
data to of With declined, for are XXXX. thinking an June how However, high-level just you balance improving I that on with falling but now X%. about update performance trend those will suggests categories the X% backdrop, we
provide objective always, assumptions identifying to current with is transparently guidance, year for that and Our key factors outlook. useful may clear full information is as influence highlighting less you, our that over coming important Similar of our to guidance to likely caveat very the is that April, impact in fluid pandemic and continue the it and update is to evolving the weeks months.
of system overall As perspective to, related such, related and the external include? evolving it in the negative sources internal to numerous that for consumer number when inform outlook. the macro insured addition COVID-XX health and near-term behavior of health frame patient individuals care consequences to on instance, care and procedures to relies related mind it on help comes Our have potential spending may does visits. and external assumptions office elective to impact upon our projections and What our financial consider expert assessments to the of
treat also with Alex, having hospital conversations that on Device administrators are system that institution. related virus, to and and their have Ashley, We relying COVID-XX numerous leaders implemented the the preparedness our to are and of the spikes Medical been for patients of capacity, economics potential surgeons improvements the
account, delve and business business. weekly quantitative into guidance, our qualitative Lastly, these we XXXX beginning extensive trends. with review on our factors let's Pharmaceutical analytics individual hospital into updated Taking for account that our
for patient health in expectations we care providers areas. are weeks patient did activity for recent Our experience which for our Pharmaceutical and starts interactions lower reduced business In unchanged. with impacted QX, we drugs, improvement but remain new seeing those physician-administered
with prescription may above-market modest in longer of QX us expect once confidence results negatively. very the Pharmaceutical a that attributable all, durations, in growth was QX gives again. offering You All addresses to need recall significant which of strength pharmacy piece impacted to XXXX providers patient slightly that strong, our strength portfolio
Regarding our Consumer Health segment.
the to changes beginning of expectations Here, had see we we year. the no at the too,
to We start reflecting year-to-date demand. Oral and versus growing a medicines grew franchises what increased are those COVID-XX to with some in X over-the-counter off in XXXX, Xx Care, fast we
partially shared, in results offset other Chris skin COVID-XX. is health/beauty, growth As that to by primarily categories, due namely
most We to assumptions with planned guidance margins. January driven to to first And then. Medical in since future ambiguous rationalization as are have what program operating SKU these are similar the are Shifting offered in proceeding the the we time. Devices. we quarter, by Changes from the mentioned at learned April improve this
is continues negative medical hospital the near-term occur most second while deferred assume and redeployed COVID-XX. the elective procedures expected, negative That impacts of to resources at April, on original and time, In industry available experience would impact year. still expectation. we start the in quarter. expectations Medical to to assumed are to the our XX% We in device Devices As a all significant all across address our the are procedures markets average XX% quarter decline second the data versus weighted based to
world slide, still Devices as As the on you quarter. can approximately XX% opening than was better economies the sooner than total around anticipated, down Medical began performed that assumption see this but in
urgent at rate June in the month by expectations. being second Importantly, the in deferrable. considered declined original XX% quarter, down with the least improvement surprisingly, approximately month versus lesser at each we the our Not we encouraged of procedures are saw a than procedures
with we ramp to the provided Medical most in difficult recovery think COVID-XX guidance in we linger the the When QX. recovery in QX and about of impact April, estimate. XXXX, of expected QX the to throughout Devices of a we is remainder the variable As
now demand thus, we experienced the However of year. result presumed a the patients noted, than to occur in is predicted as anticipated. pent-up in a earlier recovery as just originally faster QX And of we backlog
Additionally, success early Japan seeing bucketed impacted first and Korea containing guidance given country virus, these were in China we and markets was the X in when the together providing April.
you see, prior has to to As the and QX. versus first in growth can returned year market China been recover double-digit
countries overall of Germany quarter Japan implemented countries business, cases total consistent saw start other Korea expectations forward. other versus markets we Medical the However, best Devices. from in Devices and our perform business as no performing such the and declines major in representation with framework of the April some longer original our our like differently bucket rise year. therefore Medical how and are early our the restrictions, markets the new saw will are whereas together to in the each Similarly, declined U.S. bucketed of the defined as countries outperforming rest resulting going Clearly, XX%
Additionally, the communities. can across very dynamics a within country different be
procedural detailed allows country. us each at evolving within level model a granular to forecast Our
of XX% in a April provide now we to $X.X original QX, a previous decline QX impact the decline regionally sales a versus In our are QX, manner. were the billion we expectations the and X%, of and estimate X and such, on operational assuming to smaller we the buckets Devices we total Medical providing incorporated to relying XX% Considering impact all below In factors, than instead expect we Medical of negative throughout our simplified approximately January not billion largely to with the decline forecast As for ago, approximately demand to to our $X.X quarters guidance. in we based original for a Devices X. remarks start year, guidance. expectations these a QX my visibility now moment XX% consistent pent-up are from with to our a occurs are anticipating
to many operational Devices the While the prior sales parts, there on impact enterprise. for guidance are our moving Medical is the sole change
about get wave often of we second Now COVID. asked a
last the Our more available. may occurs, been assumption in they more the is if the believe, do occurs, Testing This that we, shared tests medical Remarkably, that's necessary thinking daily available. same precision. so? improve, this as be over alone. experts in based various and that of occur not X quickly is therapeutic options now to adequate supply is equipment. protocols There measures continues How much that, readily be is other by continue better implemented are world U.S. opinions XXX,XXX global being with to as and Treatment on it impact the prepared. of level if Isolation should months. have experienced there preventative
portion have Finally, population will a developed the of antibodies.
rapidly appeared. premise the better our permissible the largely care the virus in related declining to we that first visits with this death positioned case procedures system doctor death year. be the too rate, monitor virus, Therefore, will actively rising is than many, is second X while of the While is and a health rate when much half
We impact So year. were to to most earlier expected impact our occurred in QX, predicted to let's assumed to have estimate still Device in the of the what both bolus now be our is April. QX significant anticipating that is QX we but This negative guidance upside partially compared outlook. in than Medical is occurred as offset patients April now and summarize the QX less in
months contain and We serve quarters long next to long-term importantly, term while fundamentals are And seeing and few And solid. of underlying recovery. most over continue to patients customers. the our uncertainty, the see potential remain tremendous we signs the
factors, these would impact of your to reflecting we X.X% sales January positive be X.X%, guidance. comfortable latest the $X of Adjusted Medical billion operational approximately all operational range following. billion of to negative versus sales with models Device the incorporating approximately Given $X minus
Moving on to operational sales.
positive $XX.X Our guidance is $XX or X.X% billion a X.X%. billion minus to to
not in of guidance, movements, $XX.X our basis predict of euro at XXX As between basis minus to points versus the $X.XX, X.X% the reported of as April to estimated to billion. is XXX in you or X.X% approximately XXXX minus the of translation an utilizing negative billion growth resulting points do spot the we compared foreign know, sales to provided impact relative negative $XX.X estimated last rate impact currency an week dollar U.S. currency there but
are well decline operating expense. our April margins as interest as and XXX for a net other points with year-over-year income guidance of of expectation ranges We maintaining net basis
XXXX than estimated XX.X% range. for is rate tighter now to XX.X%, effective the Our be to tax guidance previous
ranging from with we of a reflects or guidance decline Given constant share earnings on constant are basis. $X.XX $X.XX an those currency to updates, X.X%. currency comfortable This operational adjusted per to X.X%
While and and portfolio XXXX, per year anticipate to would words with movements, business, IMBRUVICA, largely as for such year. $X.XX, very a by I the impact Devices, minus in from deliver adjusted continue your on business, are that, by our and our In key for TREMFYA, channel. $X.XX operational approximately ranging not thinking $X.XX. reflecting increased be few indications by but the diversified so performance, or penetration our our e-commerce expect of in focus on we expansion another to on we I across DARZALEX, new double-digit biosimilar EPS Consumer insights of impacted we procedures strongholds you on Health skin competitors today, of existing to our we expect April X.X%. to the Accounting we guidance products negative largely on reported of EPS, what driven XXXX, ERLEADA. know solid adjusted continued predicting STELARA OTC would versus share potential core currency $X.XX led and reported impact models above-market comfortable negatively new generic will And impact some throughout provide would next robust In be a growth given early COVID-XX's based beyond thought of of on I Medical many a say thoughts on expect Pharmaceutical don't permissible growth. health and sales EPS year. to to delivering interested select XX.X% we In minus our topics our know range be
for P&L the XXXX. Regarding
consistent expecting I we for very expense guidance While XXXX. not be income share with are guidance that will just at the other shared to this and early stage, providing I
X calendar XXrd growth XXXX. play associated success, finalized planning as higher initiative XXXX well developed and as basis on to calls. future we improve would significant given rigor, our benefits providing SKU XXXX going And this treat days gains to operating being future from rationalization margins are in where plans year, We comparing this operational commit finally, appropriate will on dynamics portfolio a In at reminder, platforms of EPS our shipping Health. expect given emphasizing Consumer our can be when to has throughout X with forward. Robust as a we to to the we while We and are continue fiscal additional addition, sales as level realizing item in versus week. with updates manage we some XXXX, move year special a earnings anticipate the from as an next benefit optimize strong our in as revenue year's divestiture of
Let me conclude key developments prepared with the quarter. remarks our in
we our but majority able a a As pipeline, few Pharmaceutical highlight pipeline. with like advance the we have portfolio been items. our look I'd Beginning to despite at COVID-XX, to of
updated several updated in for remain CLL and EU which commercial our frontline arthritis U.S. We line the regulatory to plans. slightly manufacturing in active in vaccine year-end XXXX, ahead the IMBRUVICA number on the notable U.S. In development TREMFYA the for We our and progress of of track a Paul comprehensive XXXX the quarter the and on in the of U.S. Most submission Ebola EU. slide, application psoriatic PDUFA by on time with we formulation our to had addition BCMA their second approvals rituximab DARZALEX have combo and COVID-XX the of dates. U.S., for included to filing timing referenced accounts the subcutaneous EU, for initiate in vaccine CAR-T. the early are candidate, in this
The FDA no supported GALAHAD study which prostate safety we from demonstrate castration-resistant therapy Phase a in II line cancer. did breakthrough efficacy designation. note niraparib are that will metastatic longer filing X for and data You niraparib, profile also competitive the highly
in will to niraparib agents important development, other this submissions we GALAHAD, have approval niraparib with an potential. accelerated of not moving our on single-arm of revenue remains prostate path gain removed pipeline, based be but approvals with this cancer study. this forward recent However, $X-billion-plus with the part for class Considering regulatory
to Turning Medical Devices.
microcatheter balloon for a treatment, ablation CE Mark advance Mark U.S. designation catheter; in to and achievements We innovation CE with breakthrough FDA continue some Monarch-enabled our NeuWave such for just as: technology; few. Heliostar, agenda to lesion QDOT, quarter, enabling for better a our notable highlight single-shot the
using We completed lung also have offerings. to over system. been continued the X,XXX biopsies advance digital launch, surgery there Since Monarch
with a multi-specialty in market almost kidney twice line stones, size in of U.S. we is with We applications will also one the that of next approval the are treatment endourology the expand system for today. with the
proposition General a of increases surgery of our for we ability enhances and our VELYS knees, both in the to coming continue incorporate we and progress Surgery, believe orthopedic create of first We make platforms from out to robotics our surgery a robotic acquisition as regulatory half great of submission will In differentiated Orthotaxy. U.S. XXXX part general Auris, elements second which value surgeons. Verb our towards digital our platform, for solution platform
continue solution the world. will these our a around analyzing regulatory pathway regulatory market goal studies XXX(k) time initiate compared robotic After value based conversations, be in XXXX. proposition, not conversations to our on And of We to have U.S. with authorities with the is following to the overall ongoing first-in-human we half to in second
few The world Idorsia. offer months Corporation's based is excited We and competitive the was the to continued product the and a close it sale of that this short second on for that will on here ago. Johnson occurring lines about in a very not than program continue and just different One equity know our item Development quarter better with listed patients. today, slide after time are market what outcomes differentiated Johnson new was very be overall a what investment to we position the & reflecting
formation of a ongoing that is company, deal the Actelion innovative remain with very resulting partnership our new which we Ponesimod We Aprocitentan. established. employed in you XXXX, an excited Idorsia about assets now of on structure recall part like the may acquisition As and in
remain values doctors not and back Chris, portion. children, begin and to and them, tumultuous communities be our standards with Before sincere effort meeting call back XXX,XXX to strong our around on to and to shareholders. current In patients, Without possible. success the their focused Q&A & you I gratitude want Johnson's tireless dedication to express associates and credo they world. commitments unwavering the and elevating the care. employees, foundations to would of Johnson future hand I the year, our Chris, begin nurses, parents to health a
